[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-therapy-patient\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-therapy-patient":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,78,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054031","targeted-oligometastatic-radiation-in-pediatric-and-young-adult-patients-with-soft-tissue-and-bone-sarcoma-100054031",false,"NCT06796543","Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma","TARGET-RT","Stratum A Inclusion Criteria:\n\n* Patients must be aged \\\u003C 39 years at time of enrollment.\n* Patients must have a Karnofsky or Lansky performance score of 70 or greater or Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Patients must have newly diagnosed histologically or molecularly confirmed soft tissue or bone sarcoma at any site.\n* Patients must have metastatic disease that is measurable and this is defined as at least one lesion discontinuous from the primary that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\> 3mm with CT scan within 3 weeks from treatment start.\n\nStratum B Inclusion Criteria:\n\n* Patients must have a Karnofsky or Lansky performance score of 70 or greater or ECOG performance status of 0-1.\n* Patients must have radiographic, histologic or molecular confirmation of progressive soft tissue or bone sarcoma at any site that was initially diagnosed at age \\\u003C 39 years. Progression includes progression at a new site or known sites of prior disease (e.g. recurrent).\n* Patients must have metastatic disease that is measurable and this is defined as at least one lesion discontinuous from the primary that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\> 3mm with CT scan\n* Radiation to at least one site is being recommended as part of second line therapy.\n\nStratum A Exclusion Criteria:\n\n* Brain or intracranial metastases, including leptomeningeal disease\n* Clinical or radiologic evidence of spinal cord compression requiring emergent radiation treatment\n* Positive bone marrow biopsy for non-pelvic primary and greater than eight bone metastases. Presence of parenchymal lung metastases is considered as one metastasis, irrespective of how many lung nodules are present.\n* Evidence of any non-measurable metastatic disease including but not limited to leptomeningeal disease, malignant ascites and malignant pleural or pericardial effusions.\n* Pregnancy\n\nStratum B Exclusion Criteria:\n\n* Brain or intracranial metastases, including leptomeningeal disease\n* Clinical or radiologic evidence of spinal cord compression requiring emergent radiation treatment\n* Evidence of any non-measurable metastatic disease including but not limited to leptomeningeal disease, malignant ascites and malignant pleural or pericardial effusions.\n* Pregnancy","ALL","39 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.",[26,27,28,29],"Metastatic Sarcoma","Radiation Therapy Patient","Ewing Sarcoma","Rhabdomyosarcoma",[31,26,32,29,33,34,35],"Pediatric","Ewing sarcoma","Brain tumor","Longitudinal","Radiation Therapy","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2025-03-25",{"date":44,"type":20},"2030-03",{"name":46,"class":47},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100627366","a-pilot-study-to-evaluate-the-effectiveness-of-focused-massage-on-pain-mobility-and-quality-of-life-during-radiation-treatment-for-patients-with-breast-cancer-100627366","NCT07447700","A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Diagnosis of breast cancer\n3. Treatment plan for curative intent radiation at SSBC\n4. Radiation treatment frequency can be daily, every other day, and twice weekly\n5. Agreeable to and available for focused chair massages post-radiation treatments during the prescribed treatment period\n\nExclusion Criteria:\n\n1. Patients with recurrent disease (breast cancer)\n2. Patients treated palliatively with radiation treatments\n3. Inability to read and\u002For understand English (consent and questionnaires in English)\n4. Patients with documented cognitive disorder that limits the ability to independently read, understand, and\u002For complete the survey measures; i.e. dementia, Alzheimer's\n5. Patients with major psychiatric disorders not controlled by medication or other psychiatric treatments","18 Years",{"count":57,"type":20},55,[23],"The goal of this interventional study is to to evaluate the effectiveness and acceptability of a focused upper body massage when offered after radiation treatments to participants diagnosed with breast cancer. Given the prevalence of musculoskeletal complaints during radiation therapy delivery and acknowledging the emotional stress associated with breast cancer diagnosis and treatment, the aims of this pilot study are to: 1) evaluate the effectiveness of a focused upper body massage, available after radiation treatments, on patient's muscle and joint achiness and disability\u002Fsymptoms of the upper extremities; 2) evaluate the effectiveness of a focused chair massage, available after radiation treatments on health-related quality of life; 3) assess the need for repeating the pre-radiation simulation process and revising the established treatment plan; and 4) and evaluate patient acceptability of the massages offered during the course of radiation treatment.",[61,27],"Breast Cancer",[63,64,65,66,67],"breast cancer","radiation therapy","muscle and joint achiness","quality of life","re-simulation","2026-06-30",{"date":70,"type":40},"2026-07-02",{"date":72,"type":40},"2026-04-01",{"date":74,"type":20},"2027-08-30",{"name":76,"class":47},"Ohio State University Comprehensive Cancer Center",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100630570","concomitant-use-of-radiotherapy-and-integrated-exercise---lung-cancer-100630570","NCT07489391","Concomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer","Effect of an Integrated Exercise Program Concomitant With Radiotherapy on Functional Capacity in Patients With Lung Cancer","Inclusion Criteria:\n\n* Histological diagnosis of non-small cell lung cancer (NSCLC) at stage II-III (locally advanced), unresectable\u002Finoperable.\n* Candidate for radical radiotherapy with concomitant chemotherapy, with or without maintenance Durvalumab.\n* ECOG performance status ≤2 (or Karnofsky index ≥60).\n* Ability to communicate adequately with the research team and to complete questionnaires and functional tests.\n* Signed written informed consent after receiving detailed information about the study.\n\nExclusion Criteria:\n\n* Decompensated cardiorespiratory comorbidities that contraindicate moderate-intensity physical exercise:\n\n  * New York Heart Association (NYHA) class III-IV congestive heart failure or unstable angina.\n  * Recent myocardial infarction (\\\u003C6 months) or uncontrolled arrhythmias.\n  * Very severe chronic obstructive pulmonary disease (COPD) GOLD IV with recent exacerbations, permanent home oxygen therapy, or severe pulmonary hypertension.\n* Severe physical or neurological limitations that prevent exercise.\n* Absolute medical contraindications to inspiratory muscle training: unresolved pneumothorax, recent thoracic surgery (\\\u003C4 weeks), or active hemoptysis.\n* Refusal or inability to understand\u002Ffollow the program instructions (e.g., severe cognitive impairment, insurmountable language barrier).",{"count":86,"type":20},10,[23],"Study objective and procedures\n\nThe objective of CURIE-LC is to evaluate the feasibility (i.e., whether it is possible and safe) of carrying out a comprehensive exercise program during combined radiotherapy and chemotherapy in patients with lung cancer. The study will assess whether patients can adhere to the exercise program while receiving oncologic treatment and will explore its effects on physical fitness and quality of life.\n\nWhat does participation involve?\n\nIf participants choose to take part, they will join a supervised exercise program conducted throughout the chemoradiotherapy treatment. The program includes three main components, tailored to the individuals' abilities:\n\nInspiratory breathing exercise: training with a specialized device to strengthen the breathing muscles and improve lung capacity.\n\nAerobic exercise: moderate-intensity aerobic activity (e.g., treadmill walking or stationary cycling) several days per week to improve endurance and cardiovascular health.\n\nStrength training: muscle-strengthening exercises (e.g., light weights or resistance bands) twice per week to maintain or increase arm and leg strength.\n\nA physiotherapist or other trained professional will guide the participant at all times to ensure exercises are performed safely and appropriately. Sessions will last approximately 20 to 60 minutes and will be coordinated with the radiotherapy\u002Fchemotherapy schedule so as not to interfere with the treatment.\n\nIn addition to the exercise sessions, participants will undergo physical assessments and complete questionnaires at several time points. Before starting and at the end of the program, the investigagtors will measure functional capacity using the 6-minute walk test (6MWT) and assess respiratory muscle strength using maximal inspiratory and expiratory pressures (PImax and PEmax). Handgrip strength will also be measured. Participants will complete questionnaires about health status, fatigue, mood, and quality of life. These evaluations will help determine the impact of exercise during treatment.\n\nThe exercise program will last for the duration of the treatment, approximately 7 to 9 weeks, with a short-term follow-up after treatment ends. Overall, participation involves attending the scheduled weekly exercise sessions during treatment, plus several evaluation visits (before, during, at the end of the program, and a few months later). Exact timing and frequency will be explained and planned according to the individual situation, aiming to minimize disruption to daily routine.",[90,27,91],"Non Small Cell Lung Cancer","Stage II\u002FIII",[93,94,95],"Lung Cancer","Exercise","Radiochemotherapy","2026-04-30",{"date":98,"type":40},"2026-05-06",{"date":100,"type":20},"2026-04",{"date":102,"type":20},"2026-12",{"name":104,"class":47},"University of Deusto",2,{"id":107,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":24,"conditions":110,"keywords":111,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":117,"locationsCount":105},"100577303",{"count":19,"type":20},[23],[26,27,28,29],[31,26,32,29,33,34,35],"2026-04-17",{"date":114,"type":40},"2026-04-20",{"date":42,"type":40},{"date":44,"type":20},{"name":46,"class":47}]